Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. No abstract available.

PMID:
30770493
2.

Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):875. doi: 10.1158/0008-5472.CAN-18-4087. No abstract available.

PMID:
30770370
3.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
4.

Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2019 Feb;9(2):303. doi: 10.1158/2159-8290.CD-18-1515. No abstract available.

PMID:
30737217
5.

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2017 Jun 15;77(12):3280-3292. doi: 10.1158/0008-5472.CAN-16-2808. Epub 2017 Apr 10. Erratum in: Cancer Res. 2019 Feb 15;79(4):873.

6.

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1434.

7.

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2017 Jun;7(6):575-585. doi: 10.1158/2159-8290.CD-16-1431. Epub 2017 Mar 8. Erratum in: Cancer Discov. 2019 Feb;9(2):303.

8.

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2016 Jan 15;76(2):440-52. doi: 10.1158/0008-5472.CAN-15-1640-T. Epub 2015 Dec 16. Erratum in: Cancer Res. 2019 Feb 15;79(4):875.

9.

Computational investigation of drug action on human-induced stem cell-derived cardiomyocytes.

Frotscher R, Koch JP, Staat M.

J Biomech Eng. 2015 Jul;137(7). doi: 10.1115/1.4030173. Epub 2015 Jun 2.

PMID:
25807216
10.

cAMP-dependent activation of CFTR inhibits the epithelial sodium channel (ENaC) without affecting its surface expression.

Konstas AA, Koch JP, Korbmacher C.

Pflugers Arch. 2003 Jan;445(4):513-21. Epub 2002 Nov 30.

PMID:
12548398
11.

The role of individual Nedd4-2 (KIAA0439) WW domains in binding and regulating epithelial sodium channels.

Fotia AB, Dinudom A, Shearwin KE, Koch JP, Korbmacher C, Cook DI, Kumar S.

FASEB J. 2003 Jan;17(1):70-2. Epub 2002 Nov 1.

PMID:
12424229
12.

Cystic fibrosis transmembrane conductance regulator-dependent up-regulation of Kir1.1 (ROMK) renal K+ channels by the epithelial sodium channel.

Konstas AA, Koch JP, Tucker SJ, Korbmacher C.

J Biol Chem. 2002 Jul 12;277(28):25377-84. Epub 2002 May 6.

13.
14.
15.
16.

Nifedipine-induced gingival hyperplasia.

Silverstein LH, Koch JP, Shatz PC.

Am Fam Physician. 1996 Mar;53(4):1069-70. No abstract available.

PMID:
8629555
17.

Evaluation, diagnosis, and treatment planning of complex implant cases.

Mills EJ, Dunson BC, Koch JP.

J Oral Implantol. 1996;22(1):12-6. No abstract available.

PMID:
8957881
18.

Factors affecting bone healing following implant surgery.

Koch JP, Dunson B.

J Oral Implantol. 1996;22(1):7-11. Review. No abstract available.

PMID:
8957880
19.

Nifedipine-induced gingival enlargement around dental implants: a clinical report.

Silverstein LH, Koch JP, Lefkove MD, Garnick JJ, Singh B, Steflik DE.

J Oral Implantol. 1995;21(2):116-20.

PMID:
8699502
20.

Determinants of low systemic vascular resistance during cardiopulmonary bypass.

Christakis GT, Fremes SE, Koch JP, Harwood S, Juhasz S, Sharpe E, Deemar KA, Hamilton C, Chen E, Rao V, et al.

Ann Thorac Surg. 1994 Oct;58(4):1040-9.

PMID:
7944747
21.

A randomized study of the systemic effects of warm heart surgery.

Christakis GT, Koch JP, Deemar KA, Fremes SE, Sinclair L, Chen E, Salerno TA, Goldman BS, Lichtenstein SV.

Ann Thorac Surg. 1992 Sep;54(3):449-57; discussion 457-9.

PMID:
1510511
22.

The safety of awake tracheal intubation in cervical spine injury.

Meschino A, Devitt JH, Koch JP, Szalai JP, Schwartz ML.

Can J Anaesth. 1992 Feb;39(2):114-7.

PMID:
1544191
23.

Anaesthetic management of acute blunt thoracic trauma.

Devitt JH, McLean RF, Koch JP.

Can J Anaesth. 1991 May;38(4 Pt 1):506-10.

PMID:
2065419
24.

Formalization and implementation of an institutional preanaesthetic checklist.

Hunziker P, Koch JP, Devitt JH.

Can J Anaesth. 1990 May;37(4 Pt 2):S9. No abstract available.

PMID:
2361326
25.

Anesthesia for open lung biopsy in a patient with intracardiac tumor.

Kay J, Koch JP.

Anesthesiology. 1989 Oct;71(4):607-10. No abstract available.

PMID:
2802221
26.

Early identification of high-risk patients using the "estimated" injury severity score and age.

McLellan BA, Koch JP, Wortzman D, Rogers C, Szalai J, Williams D.

Accid Anal Prev. 1989 Jun;21(3):283-90.

PMID:
2736025
27.

The use of halothane in the treatment of status asthmaticus.

Bayliff CD, Koch JP, Faclier G.

Drug Intell Clin Pharm. 1985 Apr;19(4):307-9.

PMID:
4006721
28.

Mechanical aids for fiberoptic endoscopy.

Patil V, Stehling LC, Zauder HL, Koch JP.

Anesthesiology. 1982 Jul;57(1):69-70. No abstract available.

PMID:
7091730
29.
30.
31.

Changes in peripheral vascular and cardiac sympathetic activity before and after coronary artery bypass surgery: interrelationships with hemodynamic alterations.

Kim YD, Jones M, Hanowell ST, Koch JP, Lees DE, Weise V, Kopin IJ.

Am Heart J. 1981 Dec;102(6 Pt 1):972-9.

PMID:
6976114
32.
33.

Left ventricular myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy and previous cardiac arrest.

Morrow AG, Koch JP, Maron BJ, Kent KM, Epstein SE.

Am J Cardiol. 1980 Aug;46(2):313-6.

PMID:
7190771
34.

Growth stasis by accumulated L-alpha-glycerophosphate in Escherichia coli.

Cozzarelli NR, Koch JP, Hayashi S, Lin EC.

J Bacteriol. 1965 Nov;90(5):1325-9.

35.

A SURVEY OF FOOD INTOLERANCES IN HOSPITALIZED PATIENTS.

KOCH JP, DONALDSON RM Jr.

N Engl J Med. 1964 Sep 24;271:657-60. No abstract available.

PMID:
14170845
36.

THE CONTROL OF DISSIMILATION OF GLYCEROL AND L-ALPHA-GLYCEROPHOSPHATE IN ESCHERICHIA COLI.

KOCH JP, HAYASHI S, LIN EC.

J Biol Chem. 1964 Sep;239:3106-8. No abstract available.

37.

ACTIVE TRANSPORT OF L-ALPHA-GLYCEROPHOSPHATE IN ESCHERICHIA COLI.

HAYASHI S, KOCH JP, LIN EC.

J Biol Chem. 1964 Sep;239:3098-105. No abstract available.

38.

Utilization of L-alpha-glycerophosphate by Escherichia coli without hydrolysis.

LIN EC, KOCH JP, CHUSED TM, JORGENSEN SE.

Proc Natl Acad Sci U S A. 1962 Dec 15;48:2145-50. No abstract available.

39.

Serotonin metabolism in paralysis agitans.

RESNICK RH, GRAY SJ, KOCH JP, TIMBERLAKE WH.

Proc Soc Exp Biol Med. 1962 May;110:77-9. No abstract available.

PMID:
14491558

Supplemental Content

Support Center